Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-03-27
2007-03-27
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S333000, C546S256000, C546S264000
Reexamination Certificate
active
10690671
ABSTRACT:
A bis(5-aryl-2-pyridyl) compound represented by formula (1) or a salt thereof:wherein A is a substituted or unsubstituted aromatic hydrocarbyl group or a substituted or unsubstituted aromatic heterocyclic group, and X is a group selected from the group consisting of moieties having formulas (2) to (5):wherein, in formula (2), m is an integer of 1 or 2; in formula (3), n is an integer of 1 to 6; and in formula (4), R is hydrogen or a lower alkyl group and p is an integer of 1 to 6.
REFERENCES:
patent: 0 787 491 (1997-08-01), None
patent: 59-167564 (1984-09-01), None
patent: 1-106818 (1989-04-01), None
patent: 7-017506 (1995-03-01), None
patent: 8-092216 (1996-04-01), None
patent: 8-109177 (1996-04-01), None
patent: 10-324631 (1998-12-01), None
patent: 11-269192 (1999-10-01), None
patent: WO 96/11682 (1996-04-01), None
patent: WO 98/04508 (1998-02-01), None
patent: WO 98/07702 (1998-02-01), None
patent: WO 98/16497 (1998-04-01), None
patent: WO 99/19291 (1999-04-01), None
patent: WO 99/35140 (1999-07-01), None
patent: WO 99/38829 (1999-08-01), None
patent: WO 99/42446 (1999-08-01), None
patent: WO 00/05198 (2000-02-01), None
Robert B. Fick, Jr., Current Opinion in Pulmonary Medicine, vol. 5, pp. 76-80, “Anti-IgE as Novel Therapy for the Treatment of Asthma”, 1999.
Farhad Imani, Emerging Therapeutic Targets, vol. 3, No. 2, pp. 229-240, “Emerging Therapeutic Targets in Asthma and Allergy: Modulation of IgE”, 1999.
Henry Milgrom, et al., The New England Journal of Medicine, vol. 341, No. 26, pp. 1966-1973, “Treatment of Allergic Asthma With Monoclonal Anti-IgE Antibody”, Dec. 23, 1999.
Naosuke Matsuura, et al., Jpn. Pharmacol. Ther., vol. 22, No. 3, pp. 1369-1383, “An Immunopharmacological Study of (±)—[2- [4-(3-Ethoxy-2-Hydroxypropoxy) Phenylcarbamoyl] Ethyl] DimethylsulfoniumP-Toluenesulfonate (Suplatast Tosilate, IPD-1151T)”, 1994.
U.S. Appl. No. 10/690,671, filed Oct. 23, 2003, Ishiwata et al.
U.S. Appl. No. 09/893,680, filed Jun. 29, 2001, Ishiwata et al.
Ishiwata Hiroyuki
Kabeya Mototsugu
Oda Soichi
Sato Seiichi
Shibasaki Manabu
Coleman Brenda
Kowa Co., Ltd
LandOfFree
Bis(5-aryl-2-pyridyl) derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bis(5-aryl-2-pyridyl) derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bis(5-aryl-2-pyridyl) derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3783223